All News

Screen%20Shot%202018-11-01%20at%2010.14.03%20AM_0.png

Practical management of rheumatic immune-related adverse events with immune checkpoint inhibitors

Jack Cush, MD

Joint Bone Spine has published a full read review of the management of immune-related adverse events (irAEs) in patients receiving Immune checkpoint inhibitors (ICIs) for cancer.

Read Article
US.knee_.jpg

Subclinical Synovitis Among Psoriasis Patients

Jack Cush, MD

A systematic review shows that imaging can be used to detect subclinical synovitis among patients with psoriasis and may identify individuals at risk for future psoriatic arthritis.

Read Article
Tyk2.Wikipedia

Zasocitinib (Tyk2 Inhibitor) Efficacy in Psoriatic Arthritis

Jack Cush, MD

A highly selective, tyrosine kinase 2 inhibitor zasocitinib (TAK-279), was studied in a phase 2b trial and found to be effective and safe patients with active psoriatic arthritis (PsA).

Read Article
human figures on blue circle

1 in 5 Patients are Unaware of their Arthritis Diagnosis

Jack Cush, MD

Current CDC numbers suggest that arthritis (any type) affects an estimated 67.1 million (27.9% ) adults in the USA.  Interestingly, 1 in 5 do not know their arthritis subtype (21.6%, 14.4 million).

Read Article
hospital,surgery

Variability of Guidelines on the Perioperative Use of DMARDs in Rheumatic Diseases Patients

Jack Cush, MD

More effective treatments in patients with rheumatic diseases have resulted in less need for major surgery, yet a substantial number of RMD patients will undergo surgery often in the setting of DMARDs use. A scoping review looked at numerous clinical practice guidelines/recommendations for the perioperative management of DMARDs and found inconsistencies and low quality evidence, with great reliance on conditional (expert opinion) recommendations.

Read Article
RheumNow Podcast square

Hmmm Really? (7.11.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week - some obvious, other new thoughts and some - hmmm, reallly?

Read Article
cancer search news magnify

No Increased Malignancy Risk with Ixekizumab

Jack Cush, MD

A pooled analysis of 25 randomized clinical trials affirms the safety of ixekizumab (IXE) when used to treat patients with psoriasis (PsO), psoriatic arthritis (PsA), or axial spondyloarthritis (axSpA).

Read Article
Review of risankizumab efficacy & safety included 545 psoriasis pts showing Mean PASI decreased from 14 to 0.5 at 208Wk. PASI100 achieved in 33% and 74% at 16Wk & 208Wk. Bio-naïve responded faster bio-experienced pts - only 5 pts D/C for adverse events https://t.co/VklLWpD0SF https://t.co/zZfuiFijd4

Links:

Dr. John Cush RheumNow ( View Tweet)
Subclinical Synovitis Among Psoriasis Patients A systematic review shows that imaging can be used to detect subclinical synovitis among patients with psoriasis and may identify individuals at risk for future psoriatic arthritis. https://t.co/2603Aax8PP https://t.co/2XDtDg1QHh

Links:

Dr. John Cush RheumNow ( View Tweet)
40 kids w/ Psoriasis compared to 40 juvenile PsA pts. Those w/ jPsA were more likely to be: - Obese/overweight (80 vs 17.5%) - passive smoking (37.5 vs (25%) - Signif higher ESR and CRP (P < 0.001) - Nail PsO (65 vs 22%) https://t.co/3uBHnxZYC2 https://t.co/rW48EQta2s

Links:

Dr. John Cush RheumNow ( View Tweet)
Zasocitinib (Tyk2 Inhibitor) Efficacy in Psoriatic Arthritis A highly selective, tyrosine kinase 2 inhibitor zasocitinib (TAK-279), was studied in a phase 2b trial and found to be effective and safe patients with active psoriatic arthritis (PsA). https://t.co/HB0eVLLAh6 https://t.co/5Kqopaw6wL

Links:

Dr. John Cush RheumNow ( View Tweet)
BMS announced today that the FDA has accepted for review the supplemental New Drug Application (sNDA) for Sotyktu (deucravacitinib) for the treatment of adult active psoriatic arthritis. The FDA decision (PDUFA) date is March 6, 2026. https://t.co/yMxkUP5FAw https://t.co/2teEUbWFem

Links:

Dr. John Cush RheumNow ( View Tweet)
Full read overview of new imaging modalities for inflammatory arthritis, including high-res.quantitative CT, ultra-high field MRI), PET, fluorescence optical imaging, optoacoustic imaging, contrast-enhanced ultrasonography - all with artificial intelligence analysis https://t.co/rbHiPWAAFP
Dr. John Cush RheumNow ( View Tweet)
Biologic survival study of British Assoc. of Dermatologists Biologics Register (11/07-6/23) looked at 19,034 Rx courses (median F/U 2.3 yrs), of TNFi, IL-12/23i, IL-17i, & IL-23i. IL-23i (GUS & RIS) had best survival (~1.93yrs) for efficacy & safety (broadalumab the least) https://t.co/uhomYmiUZy
Dr. John Cush RheumNow ( View Tweet)
Biologic survival study of British Assoc. of Dermatologists Biologics Register (11/07-6/23) looked at 19,034 Rx courses (median F/U 2.3 yrs), of TNFi, IL-12/23i, IL-17i, & IL-23i. IL-23i (GUS & RIS) had best survival (~1.93yrs) for efficacy & safety (broadalumab the least) https://t.co/aAULb0e3o9
Dr. John Cush RheumNow ( View Tweet)
No Increased Malignancy Risk with Ixekizumab A pooled analysis of 25 randomized clinical trials affirms the safety of ixekizumab (IXE) when used to treat patients with psoriasis (PsO), psoriatic arthritis (PsA), or axial spondyloarthritis (axSpA). The observed incidences of https://t.co/7dAoQyeq5x
Dr. John Cush RheumNow ( View Tweet)
Can you predict disease from serum biomarkers? Comparison of 5 controls, 36 individuals at risk, 74, RA, & 97 PsA pts finds RA w/ higher levels of sICAM-1, MMP1, MMP3, PP, c-Peptide, CRP SAA. Also CRP, SAA, GLP-1, GIP-1, Leptin, PP precede disease onset https://t.co/zqWxsbTSlC https://t.co/Kgv2ZAuzIR

Links:

Dr. John Cush RheumNow ( View Tweet)
Rheums! Question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. https://t.co/HsqM9xLNtP https://t.co/voONsOLeSK

Links:

Dr. John Cush RheumNow ( View Tweet)
Reducing Progression of Psoriasis to Psoriatic Arthritis Tumor necrosis factor (TNF) inhibitor therapy was effective in reducing the likelihood that psoriasis would progress to psoriatic arthritis (PsA), a retrospective study indicated. https://t.co/xOtA2Hrgue https://t.co/S522IYnFgz

Links:

Dr. John Cush RheumNow ( View Tweet)
Early DMARD Initiation Benefits in Psoriatic Arthritis Mease et al has published the results of a cohort study showing early initiation of disease-modifying antirheumatic drugs (DMARDs) in patients with psoriatic arthritis (PsA) resulted in better outcomes compared to late https://t.co/EdbnpBmnPe
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×